• Explore /
  • Poster
  • / Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.

Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.

Abstract Poster

Authors

null

Juan José Soto

Medical Oncology Department-Phase 1 Functional Unit | Catalan Institute of Oncology (ICO), L´Hospitalet De Llobregat, Barcelona, Spain

Juan José Soto , Carlos Erasun Lecuona , Sandra Llop Serna , Nuria Mulet Margalef , Agostina Stradella , Rafael Villanueva , Mariona Calvo Campos , Maria Jove Casulleras , Carmen Cuadra Amor , Ramon Salazar Soler , Marta Gil-Martin , Juan Martin-Liberal , Marc Oliva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2581)

DOI

10.1200/JCO.2022.40.16_suppl.2581

Abstract #

2581

Poster Bd #

236

Abstract Disclosures

Similar Posters

First Author: Juan José Soto

First Author: Danielle M. Pastor

First Author: Zev A. Wainberg

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Effect of adding immunotherapy to standard of care on survival in patients with esophageal cancer: Analysis of NCDB database.

Effect of adding immunotherapy to standard of care on survival in patients with esophageal cancer: Analysis of NCDB database.

First Author: SABER Ali AMIN